Prof. Beat Thürlimann - Kontakt Titel Vorname Nachname Strasse Stadt Land Telefonnummer - Research KSSG

 
Prof. Beat Thürlimann

Kontakt
Titel           Prof. Dr.

Vorname         Beat

Nachname        Thürlimann

Strasse         Rorschacherstrasse 95

Stadt           9007 St.Gallen

Land            Switzerland

Telefonnummer   ++41 71 494 20 73

E-Mail          beat.thuerlimann@kssg.ch

Webseite        www.kssg.ch/brustzentrum
Forschungsprofil
Akademischer Status

Departement           Interdisziplinäre Medizinische Dienste

Abteilung             Senologie-Zentrum Ostschweiz

                                                      2
Publikationen
             Titel

Wissensch-   Burstein H J, Curigliano G, Thürlimann B, Weber W P, Poortmans P, Regan
aftlicher    M M, Senn H J, Winer E P, Gnant M, Panelists of the St Gallen Consensus
Artikel/     Conference . Customizing local and systemic therapies for women with
Review       early breast cancer: the St. Gallen International Consensus Guidelines for
             treatment of early breast cancer 2021. Ann Oncol 2021;.

             Stoffel S T, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-
             Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D,
             Schwenkglenks M, Lupatsch J E, Mark M T. Patterns of care and economic
             consequences of using bone-targeted agents for castration-sensitive
             prostate cancer patients with bone metastases to prevent skeletal-related
             events in Switzerland - the SAKK 95/16 prostate study. Swiss Med Wkly
             2021; 151:w20464.

             Herrmann C, Morant R, Walser E, Mousavi M, Thürlimann B. Screening is
             associated with lower mastectomy rates in eastern Switzerland beyond
             stage effects. BMC Cancer 2021; 21:229.

             Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U,
             von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M,
             Caspar C B, von Moos R, Mark M. Quality of life and pain in patients with
             metastatic bone disease from solid tumors treated with bone-targeted
             agents- a real-world cross-sectional study from Switzerland (SAKK
             95/16). BMC Cancer 2021; 21:182.

             Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle D A,
             Rothgiesser K, Pagani O, Thürlimann B. Plasma HER2ECD a promising
             test for patient prognosis and prediction of response in HER2 positive
             breast cancer: results of a randomized study - SAKK 22/99. BMC Cancer
             2020; 20:114.

                                                                           3
Publikationen
             Titel

Wissensch-   Maranta A F, Broder S, fritzsche c, knauer m, Thürlimann B, Jochum W,
aftlicher    ruhstaller t. Do YOU know the Ki-67 index of your breast cancer patients?
Artikel/     Knowledge of your institution's Ki-67 index distribution and its robustness
Review       is essential for decision-making in early breast cancer. Breast 2020;
             51:120-126.

             Luen S J, Asher R, Lee C K, Savas P, Kammler R, Dell'orto P, Biasi O M,
             Demanse D, Hackl W, Thürlimann B, Viale G, Di Leo A, Colleoni M, Regan
             M M, Loi S. Identifying oncogenic drivers associated with increased risk of
             late distant recurrence in postmenopausal, estrogen receptor-positive,
             HER2-negative early breast cancer: results from the BIG 1-98 study. Ann
             Oncol 2020; 31:1359-1365.

             Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlertsen B, Harvey V J,
             Neven P, Láng I, Bonnefoi H, Wardley A, Ruepp B, Castiglione M, Coates
             A S, Gelber R D, Goldhirsch A, Colleoni M, Thürlimann B, Regan M M.
             Cumulative incidence of cardiovascular events under tamoxifen and
             letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast
             Cancer Res Treat 2020;.

             Leone J P, Cole B F, Regan M M, Thürlimann B, Coates A S, Rabaglio M,
             Giobbie-Hurder A, Gelber R D, Ejlertsen B, Harvey V J, Neven P, Láng I,
             Bonnefoi H, Wardley A, Goldhirsch A, Di Leo A, Colleoni M, Vaz-Luis I, Lin
             N U. Clinical behavior of recurrent hormone receptor-positive breast
             cancer by adjuvant endocrine therapy within the Breast International
             Group 1-98 clinical trial. Cancer 2020;.

             Kensler K H, Regan M M, Heng Y J, Baker G M, Pyle M E, Schnitt S J,
             Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi
             R M. Prognostic and predictive value of androgen receptor expression in
             postmenopausal women with estrogen receptor-positive breast cancer:
             results from the Breast International Group Trial 1-98. Breast Cancer Res
             2019; 21:30.

                                                                           4
Publikationen
             Titel

Wissensch-   Denkert C, Budczies J, Regan M M, Loibl S, Dell'Orto P, von Minckwitz G,
aftlicher    Mastropasqua M G, Solbach C, Thürlimann B, Mehta K, Blohmer J U,
Artikel/     Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R,
Review       Pfitzner B M, Dietel M, Fasching P A, Viale G. Clinical and analytical
             validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and
             GeparTrio trial: systematic modulation of interobserver variance in a
             comprehensive in silico ring trial. Breast Cancer Res Treat 2019;
             176:557-568.

             schmid s, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F,
             Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von
             Moos R, Weder P, Zaman K, ruhstaller t. Long-term responders to
             trastuzumab monotherapy in first-line HER-2+ advanced breast cancer:
             characteristics and survival data. BMC Cancer 2019; 19:902.

             Varga Z, Li Q, Jochum W, Perriard U, Rau T, Tille J C, Hawle H, Klingbiel
             D, Thürlimann B, Ruhstaller T. Ki-67 assessment in early breast cancer:
             SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci
             Rep 2019; 9:13534.

             Burstein H J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P,
             Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H J, Winer E P,
             Thürlimann B, Members of the St. Gallen International Consensus Panel
             on the Primary Therapy of Early Breast Cancer 2019 . Estimating the
             benefits of therapy for early-stage breast cancer: the St. Gallen
             International Consensus Guidelines for the primary therapy of early
             breast cancer 2019. Ann Oncol 2019; 30:1541-1557.

                                                                           5
Publikationen
             Titel

Wissensch-   Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S,
aftlicher    Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, Panel
Artikel/     Members of the St. Gallen International Expert Consensus on the Primary
Review       Therapy of Early Breast Cancer 2017 . De-escalating and escalating
             treatments for early-stage breast cancer: the St. Gallen International
             Expert Consensus Conference on the Primary Therapy of Early Breast
             Cancer 2017. Ann Oncol 2019; 30:1181.

             Burstein H J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P,
             Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H J, Winer E P,
             Thürlimann B, Members of the St. Gallen International Consensus Panel
             on the Primary Therapy of Early Breast Cancer 2019 . Estimating the
             benefits of therapy for early-stage breast cancer: the St. Gallen
             International Consensus Guidelines for the primary therapy of early
             breast cancer 2019. Ann Oncol 2019; 30:1541-1557.

             Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S,
             Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, Panel
             Members of the St. Gallen International Expert Consensus on the Primary
             Therapy of Early Breast Cancer 2017 . Corrections to "De-escalating and
             escalating treatments for early-stage breast cancer: the St. Gallen
             International Expert Consensus Conference on the Primary Therapy of
             Early Breast Cancer 2017". Ann Oncol 2019; 30:1181.

             Coates A S, Goldhirsch A, Gelber R D, Ingle J N, Thürlimann B, Senn H J.
             Reply to Does the expert panel at the St Gallen meeting provide an
             unbiased opinion about the management of women with early breast
             cancer?. Ann Oncol 2019; 20:1751-1752.

                                                                          6
Publikationen
             Titel

Wissensch-   Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-
aftlicher    Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart
Artikel/     M, Caspar C B, von Moos R. Patterns of care for patients with metastatic
Review       bone disease in solid tumors: A cross-sectional study from Switzerland
             (SAKK 95/16). J Bone Oncol 2019; 21:100273.

             Buechler S A, Gray K P, Gökmen-Polar Y, Willis S, Thürlimann B, Kammler
             R, Viale G, Leyland-Jones B, Badve S S, Regan M M. Independent
             Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-
             Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant
             Endocrine Therapy for Postmenopausal Women With Hormone Receptor-
             Positive, Early Breast Cancer. JNCI Cancer Spectr 2019; 3:pkz051.

             ruhstaller t, Giobbie-Hurder A, Colleoni M, Jensen M B, Ejlertsen B, de
             Azambuja E, Neven P, Láng I, Jakobsen E H, Gladieff L, Bonnefoi H,
             Harvey V J, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E,
             Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di
             Leo A, Gelber R D, Coates A S, Goldhirsch A, Thürlimann B, Regan M M,
             members of the BIG 1-98 Collaborative Group and the International
             Breast Cancer Study Group . Adjuvant Letrozole and Tamoxifen Alone or
             Sequentially for Postmenopausal Women With Hormone Receptor-Positive
             Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol
             2018;JCO1800440.

             Luen S J, Asher R, Lee C K, Savas P, Kammler R, Dell'orto P, Biasi O M,
             Demanse D, JeBailey L, Dolan S, Hackl W, Thürlimann B, Viale G, Colleoni
             M, Regan M M, Loi S. Association of Somatic Driver Alterations With
             Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative
             Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized
             Clinical Trial. JAMA Oncol 2018;.

                                                                           7
Publikationen
             Titel

Wissensch-   Herrmann C, Vounatsou P, Thürlimann B, Probst-Hensch N, Rothermundt
aftlicher    C, Ess S. Impact of mammography screening programmes on breast
Artikel/     cancer mortality in Switzerland, a country with different regional
Review       screening policies. BMJ Open 2018; 8:e017806.

             Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers
             H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-
             Hurder A, Regan M M, Viale G, Thürlimann B, Vergote I, Christodoulou E,
             Van Calster B, Neven P. Prognostic Value of the Progesterone Receptor by
             Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative
             Breast Cancer. Oncologist 2018;.

             Baumann M, Dani S U, Dietrich D, Hochstrasser A, Klingbiel D, Mark M T,
             Riesen W F, ruhstaller t, Templeton A J, Thürlimann B. Vitamin D levels in
             Swiss breast cancer survivors. Swiss Med Wkly 2018; 148:w14576.

             Dowsett M, Sestak I, Regan M M, Dodson A, Viale G, Thürlimann B,
             Colleoni M, Cuzick J. Integration of Clinical Variables for the Prediction of
             Late Distant Recurrence in Patients With Estrogen Receptor-Positive
             Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin
             Oncol 2018; 36:1941-1948.

                                                                              8
Publikationen
             Titel

Wissensch-   Curigliano G, Burstein H J, Winer E P, Gnant M, Dubsky P, Loibl S,
aftlicher    Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B,
Artikel/     André F, Baselga J, Bergh J, Bonnefoi H, Brucker S Y, Cardoso F, Carey L,
Review       Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P,
             Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F,
             Huang C S, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M,
             Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J,
             Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A,
             Viale G, Watanabe T, Whelan T J, Xu B. De-escalating and escalating
             treatments for early-stage breast cancer: the St. Gallen International
             Expert Consensus Conference on the Primary Therapy of Early Breast
             Cancer 2017. Ann Oncol 2018; 29:2153.

             Ess S M, Herrmann C, Bouchardy C, Neyroud I, Rapiti E, Konzelmann I,
             Bordoni A, Ortelli L, Rohrmann S, Frick H, Mousavi M, Thürlimann B.
             Impact of subtypes and comorbidities on breast cancer relapse and
             survival in population-based studies. Breast 2018; 41:151-158.

             Steger G, Lüftner D, Stöger H, Thürlimann B, Untch M. Management of
             HER2-Positive Early Breast Cancer. Breast Care (Basel) 2018;
             13:453-455.

             Wapnir I L, Price K N, Anderson S J, Robidoux A, Martín M, Nortier J W R,
             Paterson A H G, Rimawi M F, Láng I, Baena-Cañada J M, Thürlimann B,
             Mamounas E P, Geyer C E, Gelber S, Coates A S, Gelber R D, Rastogi P,
             Regan M M, Wolmark N, Aebi S, International Breast Cancer Study Group
             , NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch
             Breast Cancer Trialists' Group , Breast International Group . Efficacy of
             Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional
             Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin
             Oncol 2018; 36:1073-1079.

                                                                          9
Publikationen
             Titel

Wissensch-   Klingbiel D, Thürlimann B, Brauchli P, von Moos R. Absence of Evidence is
aftlicher    not Evidence of Absence: The Case of Non-Inferiority. Ann Oncol 2017;.
Artikel/
Review       Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S,
             Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, ,
             André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L,
             Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P,
             Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F,
             Huang C S, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow
             M, Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J,
             Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A,
             Viale G, Watanabe T, Whelan T J, Xu B. De-escalating and escalating
             treatments for early-stage breast cancer: the St. Gallen International
             Expert Consensus Conference on the Primary Therapy of Early Breast
             Cancer 2017. Ann Oncol 2017; 28:1700-1712.

             Curigliano G, Burstein H J, Winer E P, Gnant M, Dubsky P, Loibl S,
             Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, ,
             André F, Baselga J, Bergh J, Bonnefoi H, Brucker S Y, Cardoso F, Carey L,
             Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P,
             Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F,
             Huang C S, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M,
             Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J,
             Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A,
             Viale G, Watanabe T, Whelan T J, Xu B. Reply to "The St. Gallen
             International Expert Consensus on the Primary Therapy of Early Breast
             Cancer 2017: the point of view of an International Panel of Experts in
             Radiation Oncology" by Kirova et al. Ann Oncol 2017;.

                                                                          10
Publikationen
             Titel

Wissensch-   Bartlett J M S, Ahmed I, Regan M M, Sestak I, Mallon E A, Dell'orto P,
aftlicher    Thürlimann B, Seynaeve C, Putter H, Van de Velde C J H, Brookes C L,
Artikel/     Forbes J F, Viale G, Cuzick J, Dowsett M, Rea D W, . HER2 status predicts
Review       for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients
             from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J
             Cancer 2017; 79:129-138.

             Zweifel M, Thürlimann B, Riniker S, weder p, von Moos R, Pagani O,
             Bigler M, Rothgiesser K M, Pilop C, Hawle H, Brauchli P, Tapia C,
             Schoenfeld W, Sessa C, . Phase I trial of the androgen receptor
             modulator CR1447 in breast cancer patients. Endocr Connect 2017;
             6:549-556.

             Borgquist S, Giobbie-Hurder A, Ahern T P, Garber J E, Colleoni M, Láng I,
             Debled M, Ejlertsen B, von Moos R, Smith I, Coates A S, Goldhirsch A,
             Rabaglio M, Price K N, Gelber R D, Regan M M, Thürlimann B. Cholesterol,
             Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the
             BIG 1-98 Study. J Clin Oncol 2017; 35:1179-1188.

             Warschkow R, gueller u, Tarantino I, cerny t, Schmied B, Thürlimann B,
             Joerger M. Improved Survival After Primary Tumor Surgery in Metastatic
             Breast Cancer: A Propensity-adjusted, Population-based SEER Trend
             Analysis. Ann Surg 2016; 263:1188-98.

             Colleoni M, Sun Z, Price K N, Karlsson P, Forbes J F, Thürlimann B, Gianni
             L, Castiglione M, Gelber R D, Coates A S, Goldhirsch A. Annual Hazard
             Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up:
             Results From the International Breast Cancer Study Group Trials I to V. J
             Clin Oncol 2016;.

             Crombag M R B S, Joerger M, Thürlimann B, Schellens J H M, Beijnen J H,
             Huitema A D R. Pharmacokinetics of Selected Anticancer Drugs in Elderly
             Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8:.

                                                                           11
Publikationen
             Titel

Wissensch-   Colleoni M, Gray K P, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E A,
aftlicher    Gomez H L, Linderholm B K, Puglisi F, Tondini C, Kralidis E, Eniu A,
Artikel/     Cagossi K, Rauch D, Chirgwin J, Gelber R D, Regan M M, Coates A S,
Review       Price K N, Viale G, Goldhirsch A. Low-Dose Oral Cyclophosphamide and
             Methotrexate Maintenance For Hormone Receptor-Negative Early Breast
             Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol
             2016;.

             Warschkow R, cerny t, Schmied B, gueller u, Thürlimann B, Joerger M. A
             population-based analysis of secondary malignancies in breast cancer
             patients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.

             Chirgwin J H, Giobbie-Hurder A, Coates A S, Price K N, Ejlertsen B,
             Debled M, Gelber R D, Goldhirsch A, Smith I, Rabaglio M, Forbes J F,
             Neven P, Láng I, Colleoni M, Thürlimann B. Treatment Adherence and Its
             Impact on Disease-Free Survival in the Breast International Group 1-98
             Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol
             2016; 34:2452-9.

             Pagani O, Klingbiel D, ruhstaller t, Nolè F, Eppenberger S, Oehlschlegel C,
             Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B,
             Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos
             R v, Zaman K, Goldhirsch A, . Do all patients with advanced HER2
             positive breast cancer need upfront-chemo when receiving trastuzumab?
             Randomized Phase III trial SAKK 22/99. Ann Oncol 2016;.

             Senn H J, Thürlimann B, Gnant M. St.Gallen-2015 in Vienna: News from
             a successful breast cancer conference transposition!. Breast 2015;.

                                                                            12
Publikationen
             Titel

Wissensch-   Munzone E, Giobbie-Hurder A, Gusterson B A, Mallon E, Viale G,
aftlicher    Thürlimann B, Ejlertsen B, Macgrogan G, Bibeau F, Lelkaitis G, Price K N,
Artikel/     Gelber R D, Coates A S, Goldhirsch A, Colleoni M, International Breast
Review       Cancer Study Group and the BIG 1-98 Collaborative Group . Outcomes of
             special histotypes of breast cancer after adjuvant endocrine therapy with
             letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
             Ann Oncol 2015;.

             Herrmann C, Ess S, Thürlimann B, Probst-Hensch N, Vounatsou P.
             40 years of progress in female cancer death risk: a Bayesian spatio-
             temporal mapping analysis in Switzerland. BMC Cancer 2015; 15:666.

             Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D,
             Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso M
             J, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E,
             Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove
             C, Macgrogan G, Michiels S, Negreiros I, Offersen B V, Penault Llorca F,
             Pruneri G, Roche H, Russell N S, Schmitt F, Servent V, Thürlimann B,
             Untch M, van der Hage J A, van Tienhoven G, Wildiers H, Yarnold J,
             Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli T S.
             Guidelines for time-to-event end point definitions in breast cancer trials:
             results of the DATECAN initiative (Definition for the Assessment of Time-
             to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.

             Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer
             E P, Thürlimann B, Gelber R D, Colleoni M, Ejlertsen B, Debled M, Price K
             N, Regan M M, Coates A S, Goldhirsch A. Relative Effectiveness of
             Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma
             in the BIG 1-98 Trial. J Clin Oncol 2015; 33:2772-9.

                                                                           13
Publikationen
             Titel

Wissensch-   Varga Z, Cassoly E, Li Q, oehlschlegel c, Tapia C, Lehr H A, Klingbiel D,
aftlicher    Thürlimann B, ruhstaller t. Standardization for Ki-67 assessment in
Artikel/     moderately differentiated breast cancer. A retrospective analysis of the
Review       SAKK 28/12 study. PLoS ONE 2015; 10:e0123435.

             Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D,
             Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso M
             J, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E,
             Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove
             C, Macgrogan G, Michiels S, Negreiros I, Offersen B V, Penault Llorca F,
             Pruneri G, Roche H, Russell N S, Schmitt F, Servent V, Thürlimann B,
             Untch M, van der Hage J A, van Tienhoven G, Wildiers H, Yarnold J,
             Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli T S.
             Guidelines for time-to-event end point definitions in breast cancer trials:
             results of the DATECAN initiative (Definition for the Assessment of Time-
             to-event Endpoints in CANcer trials). Ann Oncol 2015;.

             Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , Dowsett M,
             Forbes J F, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A,
             Coombes R C, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L,
             Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C,
             Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer:
             patient-level meta-analysis of the randomised trials. Lancet 2015;
             386:1341-52.

             Peters S, von Moos R, Thürlimann B. [Is prescription of a therapy costing
             150,000 CHF reasonable?]. Rev Med Suisse 2015; 11:1967-72.

             Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. For choosing axillary
             treatment, and adjuvant hormonal treatment. Breast Cancer 2015;.

                                                                            14
Publikationen
             Titel

Wissensch-   Leyland-Jones B, Gray K P, Abramovitz M, Bouzyk M, Young B, Long B,
aftlicher    Kammler R, Dell'orto P, Biasi M O, Thürlimann B, Harvey V, Neven P,
Artikel/     Arnould L, Maibach R, Price K N, Coates A S, Goldhirsch A, Gelber R D,
Review       Pagani O, Viale G, Rae J M, Regan M M, BIG 1-98 Collaborative Group .
             ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant
             letrozole versus tamoxifen or their sequence for early breast cancer.
             Breast Cancer Res Treat 2015; 154:543-55.

             Hadji P, Coleman R E, Wilson C, Powles T J, Clézardin P, Aapro M, Costa
             L, Body J J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D,
             Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thürlimann B, Untch M,
             Cortes J, Martin M, Albert U S, Conte P F, Ejlertsen B, Bergh J, Kaufmann
             M, Holen I. Adjuvant bisphosphonates in early breast cancer: Consensus
             guidance for clinical practice from a European Panel. Ann Oncol 2015;.

             Leyland-Jones B, Gray K P, Abramovitz M, Bouzyk M, Young B, Long B,
             Kammler R, Dell'orto P, Biasi M O, Thürlimann B, Lyng M B, Ditzel H J,
             Harvey V J, Neven P, Treilleux I, Rasmussen B B, Maibach R, Price K N,
             Coates A S, Goldhirsch A, Pagani O, Viale G, Rae J M, Regan M M.
             CYP19A1 polymorphisms and clinical outcomes in postmenopausal
             women with hormone receptor-positive breast cancer in the BIG 1-98
             trial. Breast Cancer Res Treat 2015; 151:373-84.

             Coates A S, Winer E P, Goldhirsch A, Gelber R D, Gnant M, Piccart-
             Gebhart M, Thürlimann B, Senn H J, Panel members . -Tailoring
             therapies-improving the management of early breast cancer: St Gallen
             International Expert Consensus on the Primary Therapy of Early Breast
             Cancer 2015. Ann Oncol 2015; 26:1533-46.

                                                                          15
Publikationen
             Titel

Wissensch-   Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C,
aftlicher    Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman
Artikel/     K, Johansson H, Price K N, Gelber R D, Goldhirsch A, Coates A S, Aebi S.
Review       Bone mineral density and circulating biomarkers in the BIG 1-98 trial
             comparing adjuvant letrozole, tamoxifen and their sequences. Breast
             Cancer Res Treat 2014; 144:321-9.

             Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-
             Marsico J, Diem S, Thürlimann B, cerny t. Off-label use of anticancer
             drugs in eastern Switzerland: a population-based prospective cohort
             study. Eur J Clin Pharmacol 2014; 70:719-25.

             Aebi S, Gelber S, Anderson S J, Láng I, Robidoux A, Martín M, Nortier J W
             R, Paterson A H G, Rimawi M F, Cañada J M B, Thürlimann B, Murray E,
             Mamounas E P, Geyer C E, Price K N, Coates A S, Gelber R D, Rastogi P,
             Wolmark N, Wapnir I L, CALOR investigators . Chemotherapy for isolated
             locoregional recurrence of breast cancer (CALOR): a randomised trial.
             Lancet Oncol 2014; 15:156-63.

             Huober J, Thürlimann B. Bone targeted therapy in breast cancer - an old
             concept but still much to do. Breast Care (Basel) 2014; 9:310.

             templeton a, Ribi K, Surber C, Sun H, Hsu Schmitz S F, Beyeler M,
             Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder R C,
             Rochlitz C, von Moos R, Zaman K, Thürlimann B, ruhstaller t, Swiss
             Group for Clinical Cancer Research (SAKK) Coordinating Center .
             Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in
             breast cancer patients treated with pegylated liposomal doxorubicin
             (SAKK 92/08). Breast 2014; 23:244-9.

             knauer m, Thürlimann B. Adjuvant bisphosphonates in breast cancer
             treatment. Breast Care (Basel) 2014; 9:319-22.

                                                                           16
Publikationen
             Titel

Wissensch-   Templeton A J, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M,
aftlicher    Dietrich D, ruhstaller t. Cross-sectional study of self-reported physical
Artikel/     activity, eating habits and use of complementary medicine in breast
Review       cancer survivors. BMC Cancer 2013; 13:153.

             Goldhirsch A, Winer E P, Coates A S, Gelber R D, Piccart-Gebhart M,
             Thürlimann B, Senn H J, Panel members . Personalizing the treatment of
             women with early breast cancer: highlights of the St Gallen International
             Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
             Ann Oncol 2013; 24:2206-23.

             Joerger M, Thürlimann B. Chemotherapy regimens in early breast cancer:
             major controversies and future outlook. Expert Rev Anticancer Ther
             2013; 13:165-78.

             Huober J, Cole B F, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B,
             Bonnefoi H, Forbes J F, Neven P, Láng I, Smith I, Wardley A, Price K N,
             Goldhirsch A, Coates A S, Colleoni M, Gelber R D, Thürlimann B, BIG 1-98
             Collaborative and International Breast Cancer Study Groups . Symptoms
             of endocrine treatment and outcome in the BIG 1-98 study. Breast
             Cancer Res Treat 2013; 143:159-69.

             Zaman K, Thürlimann B, Aebi S. Optimal sequence of tamoxifen and
             aromatase inhibitors to prevent bone loss. J Clin Oncol 2013; 31:3440-1.

                                                                           17
Publikationen
             Titel

Wissensch-   Oakman C, Francis P A, Crown J, Quinaux E, Buyse M, De Azambuja E,
aftlicher    Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B,
Artikel/     Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I,
Review       Gelber R D, Piccart-Gebhart M, Viale G, Di Leo A. Overall survival benefit
             for sequential doxorubicin-docetaxel compared with concurrent
             doxorubicin and docetaxel in node-positive breast cancer--8-year results
             of the Breast International Group 02-98 phase III trial. Ann Oncol 2013;
             24:1203-11.

             Regan M M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R,
             Dell'orto P, Biasi M O, Thürlimann B, Lyng M B, Ditzel H J, Neven P,
             Debled M, Maibach R, Price K N, Gelber R D, Coates A S, Goldhirsch A,
             Rae J M, Viale G, Breast International Group (BIG) 1-98 Collaborative
             Group . CYP2D6 genotype and tamoxifen response in postmenopausal
             women with endocrine-responsive breast cancer: the breast international
             group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.

             Ribi K, Aldridge J, Phillips K A, Thompson A, Harvey V, Thürlimann B,
             Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N, Gelber R D,
             Bernhard J, BIG 1-98 Collaborative Group , International Breast Cancer
             Study Group . Subjective cognitive complaints one year after ceasing
             adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer
             2012; 106:1618-25.

             Ewertz M, Gray K P, Regan M M, Ejlertsen B, Price K N, Thürlimann B,
             Bonnefoi H, Forbes J F, Paridaens R J, Rabaglio M, Gelber R D, Colleoni M,
             Láng I, Smith I E, Coates A S, Goldhirsch A, Mouridsen H T. Obesity and
             risk of recurrence or death after adjuvant endocrine therapy with
             letrozole or tamoxifen in the breast international group 1-98 trial. J Clin
             Oncol 2012; 30:3967-75.

                                                                            18
Publikationen
             Titel

Wissensch-   Joerger M, Ess S, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann
aftlicher    I, Thürlimann B. A population-based study on the patterns of use of
Artikel/     different chemotherapy regimens in Swiss patients with early breast
Review       cancer. Swiss Med Wkly 2012; 142:w13571.

             Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann
             I, Probst-Hensch N, Ess S. A population-based study on the
             implementation of treatment recommendations for chemotherapy in early
             breast cancer. Clin Breast Cancer 2012; 12:102-9.

             Huober J, Gelber S, Goldhirsch A, Coates A S, Viale G, oehlschlegel c,
             Price K N, Gelber R D, Regan M M, Thürlimann B. Prognosis of medullary
             breast cancer: analysis of 13 International Breast Cancer Study Group
             (IBCSG) trials. Ann Oncol 2012; 23:2843-51.

             Joerger M, Thürlimann B, Savidan A, Frick H, Rageth C, Lütolf U, Vlastos
             G, Bouchardy C, Konzelmann I, Bordoni A, Probst-Hensch N, Jundt G, Ess
             S. Treatment of breast cancer in the elderly: a prospective, population-
             based Swiss study. J Geriatr Oncol 2012; 4:39-47.

             Karlsson P, Cole B F, Chua B H, Price K N, Lindtner J, Collins J P, Kovács
             A, Thürlimann B, Crivellari D, Castiglione-Gertsch M, Forbes J F, Gelber R
             D, Goldhirsch A, Gruber G, International Breast Cancer Study Group .
             Patterns and risk factors for locoregional failures after mastectomy for
             breast cancer: an International Breast Cancer Study Group report. Ann
             Oncol 2012; 23:2852-8.

                                                                           19
Publikationen
             Titel

Wissensch-   Regan M M, Price K N, Giobbie-Hurder A, Thürlimann B, Gelber R D, for
aftlicher    the International Breast Cancer Study Group and BIG 1-98 Collaborative
Artikel/     Group . Interpreting breast international group (BIG) 1-98: a
Review       randomized, double-blind, phase III trial comparing letrozole and
             tamoxifen as adjuvant endocrine therapy for postmenopausal women
             with hormone receptor-positive, early breast cancer. Breast Cancer Res
             2011; 13:209.

             Colleoni M, Giobbie-Hurder A, Regan M M, Thürlimann B, Mouridsen H,
             Mauriac L, Forbes J F, Paridaens R, Láng I, Smith I, Chirgwin J,
             Pienkowski T, Wardley A, Price K N, Gelber R D, Coates A S, Goldhirsch A.
             Analyses adjusting for selective crossover show improved overall survival
             with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J
             Clin Oncol 2011; 29:1117-24.

             Goldhirsch A, Wood W C, Coates A S, Gelber R D, Thürlimann B, Senn H
             J, Panel members . Strategies for subtypes--dealing with the diversity of
             breast cancer: highlights of the St. Gallen International Expert Consensus
             on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;
             22:1736-47.

             koeberle d, ruhstaller t, Jost L, Pagani O, Zaman K, von Moos R,
             oehlschlegel c, Crowe S, Pilop C, Thürlimann B, Swiss Group for Clinical
             Cancer Research (SAKK) . Combination of trastuzumab and letrozole
             after resistance to sequential trastuzumab and aromatase inhibitor
             monotherapies in patients with estrogen receptor-positive, HER-2-
             positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
             Endocr Relat Cancer 2011; 18:257-64.

                                                                          20
Publikationen
             Titel

Wissensch-   Viale G, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E,
aftlicher    Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, Colleoni M, Láng
Artikel/     I, Thürlimann B, Mouridsen H, Mauriac L, Gelber R D, Price K N,
Review       Goldhirsch A, Gusterson B A, Coates A S, for the BIG 1-98 Collaborative
             and International Breast Cancer Study Groups . Which patients benefit
             most from adjuvant aromatase inhibitors? Results using a composite
             measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol
             2011; 22:2201-2207.

             Bolla D, Bolla, geb. Wiedemann N, oehlschlegel c, Schoening A, Stickel J,
             Thürlimann B, Hornung R. Pseudoangiomatous stromal hyperplasia of
             breast in man: a case report. Breast J 2011; 17:311-2.

             Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann
             I, Probst-Hensch N, Ess S. A Population-Based Study on the
             Implementation of Treatment Recommendations for Chemotherapy in
             Early Breast Cancer. Clin Breast Cancer 2011;.

             Chirgwin J, Sun Z, Smith I, Price K N, Thürlimann B, Ejlertsen B,
             Bonnefoi H, Regan M M, Goldhirsch A, Coates A S, BIG 1-98 Collaborative
             and International Breast Cancer Study Groups . The advantage of
             letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger
             postmenopausal women and in those with chemotherapy-induced
             menopause. Breast Cancer Res Treat 2011; 131:295-306.

             Huober J, Baumann M, Rochlitz C, Aebi S, Güth U, von Moos R, Müller A,
             von Rohr L, Widmer I, Thürlimann B. Trastuzumab Treatment beyond
             Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss
             Breast Cancer Centers. Oncology 2011; 81:160-166.

             Mark M, Thürlimann B. Fatal pneumonitis after treatment with pegylated
             liposomal doxorubicin in a patient with metastatic breast cancer in
             complete remission. Med Oncol 2011;.

                                                                          21
Publikationen
             Titel

Wissensch-   Regan M M, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B,
aftlicher    Mauriac L, Forbes J F, Smith I, Láng I, Wardley A, Rabaglio M, Price K N,
Artikel/     Gelber R D, Coates A S, Thürlimann B, BIG 1-98 Collaborative Group ,
Review       International Breast Cancer Study Group (IBCSG) . Assessment of
             letrozole and tamoxifen alone and in sequence for postmenopausal
             women with steroid hormone receptor-positive breast cancer: the BIG
             1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol
             2011; 12:1101-8.

             Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J,
             Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S,
             on behalf of the Swiss Group for Clinical Cancer Research (SAKK) . Bone
             mineral density in breast cancer patients treated with adjuvant letrozole,
             tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study
             (SAKK 21/07). Ann Oncol 2011;.

             The Scientific Board , Harbeck N, von Minckwitz G, Thürlimann B.
             Bisphosphonates in adjuvant treatment of early breast cancer. Crit Rev
             Oncol Hematol 2010; 74S1:S1.

             Phillips K A, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V,
             Thürlimann B, Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N,
             Gelber R D, Bernhard J. Cognitive function in postmenopausal women
             receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG
             1-98 randomized trial. Breast 2010; 19:388-95.

             Brauchli P, Thürlimann B, Crowe S N, Herrmann R. What is the value of
             the 21-gene recurrence score?. J Clin Oncol 2010; 28:e671-2.

             Huober J, Thürlimann B. Bone targeted therapy in breast cancer: present
             and future. Crit Rev Oncol Hematol 2010; 74S1:S7-S10.

                                                                           22
Publikationen
             Titel

Wissensch-   Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A,
aftlicher    Thürlimann B, Giobbie-Hurder A, Viale G, Altermatt H J, Aebi S, Jaggi R.
Artikel/     Molecular risk assessment of BIG 1-98 participants by expression
Review       profiling using RNA from archival tissue. BMC Cancer 2010; 10:37.

             von Moos R, Caspar C B, Steiner R, Angst R, Inauen R, Schmieding K,
             Thürlimann B. Long-term renal safety profile of ibandronate 6 mg infused
             over 15 minutes. Onkologie 2010; 33:447-50.

             Huober J, Schoch O, templeton a, Spirig C, Thürlimann B. Interstitial
             pneumonitis after treatment with bevacizumab and pegylated liposomal
             doxorubicin in a patient with metastatic breast cancer. Chemotherapy
             2010; 56:69-70.

             Paridaens R J, Gelber S, Cole B F, Gelber R D, Thürlimann B, Price K N,
             Holmberg S B, Crivellari D, Coates A S, Goldhirsch A. Adjuvant! Online
             estimation of chemotherapy effectiveness when added to ovarian function
             suppression plus tamoxifen for premenopausal women with estrogen-
             receptor-positive breast cancer. Breast Cancer Res Treat 2010;
             123:303-10.

             Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, Thürlimann B.
             Geographic variation in breast cancer care in Switzerland. Cancer
             Epidemiol 2010; 34:116-21.

             Joerger M, Thürlimann B, Huober J. Small HER2-positive, node-negative
             breast cancer: who should receive systemic adjuvant treatment?. Ann
             Oncol 2010; 22:17-23.

             Hawle H, Hess D, Mueller A, Thürlimann B. Low-Dose Fulvestrant
             Maintained Long-Term Complete Remission after Poor Response to
             Previous Endocrine Therapies in a Patient with Advanced Breast Cancer.
             Case Rep Oncol 2010; 3:131-136.

                                                                          23
Publikationen
             Titel

Wissensch-   Baumann M, Thürlimann B, ruhstaller t. Brustzentrum Kantonsspital St.
aftlicher    Gallen – von der Multidisziplinarität zur patientinnenzentrierten
Artikel/     interdisziplinären Betriebsorganisation. Breast Care 2010; 5:188-191.
Review

             Mouridsen H T, Lønning P, Beckmann M W, Blackwell K, Doughty J,
             Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B, Gnant M. Use
             of aromatase inhibitors and bisphosphonates as an anticancer therapy in
             postmenopausal breast cancer. Expert Rev Anticancer Ther 2010;
             10:1825-1836.

             Joerger M, templeton a, koeberle d, Engler H, Riesen W F, Thürlimann B.
             Procollagen type I N-propeptide is a predictor of skeletal morbidity in
             patients with malignant osteolytic bone disease on bisphosphonates.
             Cancer Chemother Pharmacol 2010;.

             Ess S, Joerger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf
             U, Savidan A, Thürlimann B. Predictors of state-of-the-art management
             of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.

             Phillips K A, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann
             B, Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N, Gelber R D,
             Bernhard J. Cognitive function in postmenopausal breast cancer patients
             one year after completing adjuvant endocrine therapy with letrozole and/
             or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2010;.

             Joerger M, Riesen W F, Thürlimann B. Bevacizumab-associated
             hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal
             breast cancer. J Oncol Pharm Pract 2010;.

             Thürlimann B. [Commentary from the viewpoint of an advocate. "Breast
             cancer mortality in organized mammography screening in Denmark--a
             comparative Study"]. Praxis (Bern 1994) 2010; 99:1217-8.

                                                                          24
Publikationen
             Titel

Wissensch-   Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , Correa C,
aftlicher    McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L,
Artikel/     Darby S. Overview of the randomized trials of radiotherapy in ductal
Review       carcinoma in situ of the breast. J Natl Cancer Inst Monographs 2010;
             2010:162-77.

             Goldhirsch A, Ingle J N, Gelber R D, Coates A S, Thürlimann B, Senn H J,
             Panel members . Thresholds for therapies: highlights of the St Gallen
             International Expert Consensus on the primary therapy of early breast
             cancer 2009. Ann Oncol 2009; 20:1319-29.

             Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price K N, Gelber
             R D, Holmberg S B, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey M
             F, Murray E, Forbes J F, Coates A S, Goldhirsch A, International Breast
             Cancer Study Group . Is adjuvant chemotherapy of benefit for
             postmenopausal women who receive endocrine treatment for highly
             endocrine-responsive, node-positive breast cancer? International Breast
             Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009;
             116:491-500.

             Thürlimann B, Price K N, Gelber R D, Holmberg S B, Crivellari D, Colleoni
             M, Collins J, Forbes J F, Castiglione-Gertsch M, Coates A S, Goldhirsch A.
             Is chemotherapy necessary for premenopausal women with lower-risk
             node-positive, endocrine responsive breast cancer? 10-year update of
             International Breast Cancer Study Group Trial 11-93. Breast Cancer Res
             Treat 2009; 113:137-44.

             Pagani O, Price K N, Gelber R D, Castiglione-Gertsch M, Holmberg S B,
             Lindtner J, Thürlimann B, Collins J, Fey M F, Coates A S, Goldhirsch A,
             International Breast Cancer Study Group (IBCSG) . Patterns of
             recurrence of early breast cancer according to estrogen receptor status:
             a therapeutic target for a quarter of a century. Breast Cancer Res Treat
             2009; 117:319-24.

                                                                           25
Publikationen
             Titel

Wissensch-   templeton a, Thürlimann B, Joerger M. Ixabepilon bei lokal
aftlicher    fortgeschrittenem oder metastasiertem Mammakarzinom: Neue
Artikel/     Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer
Review       Krebsbulletin 2009;114-117.

             Joerger M, Senn H J, Thürlimann B. St. Gallen 2009 recommendations on
             the treatment of early breast cancer: consensus and controversy.
             magazine of european medical oncology 2009; 2:229-231.

             ruhstaller t, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, koeberle
             d, Mueller U, Hoefliger M, Hess D, boehme c, Thürlimann B. Breast
             cancer patients on endocrine therapy reveal more symptoms when self-
             reporting than in pivotal trials: an outcome research study. Oncology
             2009; 76:142-8.

             BIG 1-98 Collaborative Group , Mouridsen H, Giobbie-Hurder A,
             Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J F,
             Price K N, Regan M M, Gelber R D, Coates A S. Letrozole therapy alone or
             in sequence with tamoxifen in women with breast cancer. NEJM 2009;
             361:766-76.

             Rabaglio M, Sun Z, Price K N, Castiglione-Gertsch M, Hawle H,
             Thürlimann B, Mouridsen H, Campone M, Forbes J F, Paridaens R J,
             Colleoni M, Pienkowski T, Nogaret J M, Láng I, Smith I, Gelber R D,
             Goldhirsch A, Coates A S, BIG 1-98 Collaborative and International
             Breast Cancer Study Groups . Bone fractures among postmenopausal
             patients with endocrine-responsive early breast cancer treated with 5
             years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009;
             20:1489-98.

             Huober J, Thürlimann B. Adjuvant! When the new world meets the old
             world. The Lancet 2009; 10:1028-9.

                                                                           26
Publikationen
             Titel

Wissensch-   Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO
aftlicher    2009: What's new in breast cancer therapy?. Breast Care 2009;
Artikel/     4:268-271.
Review       Huober J, Thürlimann B. Polychemotherapy in metastatic breast cancer -
             pro. Breast Care 2009; 4:367-372.

             Huober J, Thürlimann B. The Role of Combination Chemotherapy in the
             Treatment of Patients with Metastatic Breast Cancer. Breast Care (Basel)
             2009; 4:367-372.

             Ess S, Savidan A, Bouchardy C, Bordoni A, Konzelmann I, Jundt G, Probst
             N, Frick H, Thürlimann B. Patterns of care of breast cancer patients in
             Switzerland: A population based study : Advisory Board: Bachmann G,
             St.Gallen (Public Health), Lütolf U, Zurich (Radio Oncology), Obrist R,
             Sion (Medical Oncology), Rageth Ch, Zurich (Breast Surgery), Vlastos G,
             Geneva (Breast Surgery), Thürlimann B, St.Gallen (Medical Oncology).
             http://www.krebsliga-sg.ch/de/krebsregister/index.cfm 2009;.

             Giobbie-Hurder A, Price K N, Gelber R D, International Breast Cancer
             Study Group , BIG 1-98 Collaborative Group . Design, conduct, and
             analyses of Breast International Group (BIG) 1-98: a randomized,
             double-blind, phase-III study comparing letrozole and tamoxifen as
             adjuvant endocrine therapy for postmenopausal women with receptor-
             positive, early breast cancer. Clin Trials 2009; 6:272-87.

             Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO
             2009: What's New in Breast Cancer Therapy?. Breast Care (Basel) 2009;
             4:268-271.

                                                                          27
Publikationen
             Titel

Wissensch-   Colleoni M, Sun Z, Martinelli G, Basser R L, Coates A S, Gelber R D,
aftlicher    Green M D, Peccatori F, Cinieri S, Aebi S, Viale G, Price K N, Goldhirsch A,
Artikel/     International Breast Cancer Study Group . The effect of endocrine
Review       responsiveness on high-risk breast cancer treated with dose-intensive
             chemotherapy: results of International Breast Cancer Study Group Trial
             15-95 after prolonged follow-up. Ann Oncol 2009; 20:1344-51.

             Joerger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we
             stand?. Breast 2009; 18 Suppl 3:S78-82.

             Jakesz R, Dubsky P, Eidtman H, Schem C, Lang A, Thürlimann B. Neue
             Erkenntnisse vom SABCS, Expert Discussion. Breast Care 2009; 4:55-60.

             Thürlimann B. Some comments to the Pattern of Care Study. Schweiz.
             Krebsbulletin 2009; 3:212-212.

             Spirig C, Thürlimann B, Huober J. [New treatment approaches in breast
             cancer]. Therapeutische Umschau. Revue thérapeutique 2008;
             65:207-10.

             Viale G, Giobbie-Hurder A, Regan M M, Coates A S, Mastropasqua M G,
             Dell'Orto P, Maiorano E, MacGrogan G, Braye S G, oehlschlegel c, Neven
             P, Orosz Z, Olszewski W P, Knox F, Thürlimann B, Price K N, Castiglione-
             Gertsch M, Gelber R D, Gusterson B A, Goldhirsch A, Breast International
             Group Trial 1-98 . Prognostic and predictive value of centrally reviewed
             Ki-67 labeling index in postmenopausal women with endocrine-
             responsive breast cancer: results from Breast International Group Trial
             1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;
             26:5569-75.

             Huober J, Thürlimann B. [Adjuvant endocrine therapy in breast cancer].
             Therapeutische Umschau. Revue thérapeutique 2008; 65:193-200.

                                                                            28
Publikationen
             Titel

Wissensch-   Pestalozzi B C, Zahrieh D, Mallon E, Gusterson B A, Price K N, Gelber R D,
aftlicher    Holmberg S B, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G,
Artikel/     Castiglione-Gertsch M, Coates A S, Goldhirsch A, International Breast
Review       Cancer Study Group . Distinct clinical and prognostic features of
             infiltrating lobular carcinoma of the breast: combined results of 15
             International Breast Cancer Study Group clinical trials. JCO 2008;
             26:3006-14.

             Strasser F, Lutz T A, Maeder M T, Thürlimann B, bueche d, Tschöp M,
             Kaufmann K, Holst B, Brändle M, Von Moss R, cerny t, Demmer-
             Steingruber R. Safety, tolerability and pharmacokinetics of intravenous
             ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-
             controlled, double-blind, double-crossover study. BJC 2008; 98:300-8.

             Greuter S, Schmid F, ruhstaller t, Thürlimann B. Bevacizumab-associated
             osteonecrosis of the jaw. Ann Oncol 2008; 19:2091-2.

             Gruber G, Cole B F, Castiglione-Gertsch M, Holmberg S B, Lindtner J,
             Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey M F,
             Gelber R D, Coates A S, Price K N, Goldhirsch A, Viale G, Gusterson B A,
             International Breast Cancer Study Group . Extracapsular tumor spread
             and the risk of local, axillary and supraclavicular recurrence in node-
             positive, premenopausal patients with breast cancer. Ann Oncol 2008;
             19:1393-401.

             Strasser F, Demmer-Steingruber R, boehme c, Schmitz S F H, Thürlimann
             B, cerny t, gillessen s. Prevention of docetaxel- or paclitaxel-associated
             taste alterations in cancer patients with oral glutamine: a randomized,
             placebo-controlled, double-blind study. The Oncologist 2008; 13:337-46.

                                                                           29
Publikationen
             Titel

Wissensch-   Aapro M, Abrahamsson P A, Body J J, Coleman R E, Colomer R, Costa L,
aftlicher    Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi G N, Jonat W,
Artikel/     Lipton A, Monnier A, Paterson A H G, Rizzoli R, Saad F, Thürlimann B.
Review       Guidance on the use of bisphosphonates in solid tumours:
             recommendations of an international expert panel. Ann Oncol 2008;
             19:420-32.

             von Moos R, Caspar C B, Thürlimann B, angst r, inauen r, Greil R,
             Bergstrom B, Schmieding K, Pecherstorfer M. Renal safety profiles of
             ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label
             study. Ann Oncol 2008; 19:1266-70.

             Coates A, Mouridsen H, Thürlimann B, BIG 1-98 Collaborative Group .
             Inappropriate ATAC on tamoxifen. The Lancet 2008; 9:315-6.

             Bernhard J, Zahrieh D, Zhang J J, Martinelli G, Basser R, Hürny C, Forbes
             J F, Aebi S, Yeo W, Thürlimann B, Green M D, Colleoni M, Gelber R D,
             Castiglione-Gertsch M, Price K N, Goldhirsch A, Coates A S, International
             Breast Cancer Study Group . Quality of life and quality-adjusted survival
             (Q-TWiST) in patients receiving dose-intensive or standard dose
             chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.

             von Moos R, Thürlimann B, Aapro M, Rayson D, Harrold K, Sehouli J,
             Scotte F, Lorusso D, Dummer R, Lacouture M E, Lademann J, Hauschild
             A. Pegylated liposomal doxorubicin-associated hand-foot syndrome:
             recommendations of an international panel of experts. EJO 2008;
             44:781-90.

                                                                          30
Publikationen
             Titel

Wissensch-   Rasmussen B B, Regan M M, Lykkesfeldt A E, Dell'Orto P, Del Curto B,
aftlicher    Henriksen K L, Mastropasqua M G, Price K N, Méry E, Lacroix-Triki M,
Artikel/     Braye S, Altermatt H J, Gelber R D, Castiglione-Gertsch M, Goldhirsch A,
Review       Gusterson B A, Thürlimann B, Coates A S, Viale G, BIG 1-98 Collaborative
             and International Breast Cancer Study Groups . Adjuvant letrozole versus
             tamoxifen according to centrally-assessed ERBB2 status for
             postmenopausal women with endocrine-responsive early breast cancer:
             supplementary results from the BIG 1-98 randomised trial. The Lancet
             2008; 9:23-8.

             Crivellari D, Sun Z, Coates A S, Price K N, Thürlimann B, Mouridsen H,
             Mauriac L, Forbes J F, Paridaens R J, Castiglione-Gertsch M, Gelber R D,
             Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith I E,
             Chirgwin J H, Goldhirsch A. Letrozole compared with tamoxifen for elderly
             patients with endocrine-responsive early breast cancer: the BIG 1-98
             trial. JCO 2008; 26:1972-9.

             Regan M M, Pagani O, Walley B, Torrisi R, Perez E A, Francis P, Fleming G
             F, Price K N, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates A S,
             Goldhirsch A, Gelber R D, SOFT/TEXT/PERCHE Steering Committee ,
             International Breast Cancer Study Group . Premenopausal endocrine-
             responsive early breast cancer: who receives chemotherapy?. Ann Oncol
             2008; 19:1231-41.

             Mouridsen H, Keshaviah A, Coates A S, Rabaglio M, Castiglione-Gertsch
             M, Sun Z, Thürlimann B, Mauriac L, Forbes J F, Paridaens R, Gelber R D,
             Colleoni M, Smith I, Price K N, Goldhirsch A. Cardiovascular adverse
             events during adjuvant endocrine therapy for early breast cancer using
             letrozole or tamoxifen: safety analysis of BIG 1-98 trial. JCO 2007;
             25:5715-22.

                                                                          31
Publikationen
             Titel

Wissensch-   Viale G, Regan M M, Maiorano E, Mastropasqua M G, Dell'Orto P,
aftlicher    Rasmussen B B, Raffoul J, Neven P, Orosz Z, Braye S, oehlschlegel c,
Artikel/     Thürlimann B, Gelber R D, Castiglione-Gertsch M, Price K N, Goldhirsch A,
Review       Gusterson B A, Coates A S. Prognostic and predictive value of centrally
             reviewed expression of estrogen and progesterone receptors in a
             randomized trial comparing letrozole and tamoxifen adjuvant therapy for
             postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;
             25:3846-52.

             Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann B, Senn H
             J, 10th St. Gallen conference . Progress and promise: highlights of the
             international expert consensus on the primary therapy of early breast
             cancer 2007. Ann Oncol 2007; 18:1133-44.

             Karlsson P, Cole B F, Price K N, Coates A S, Castiglione-Gertsch M,
             Gusterson B A, Murray E, Lindtner J, Collins J P, Holmberg S B, Fey M F,
             Thürlimann B, Crivellari D, Forbes J F, Gelber R D, Goldhirsch A, Wallgren
             A. The role of the number of uninvolved lymph nodes in predicting
             locoregional recurrence in breast cancer. JCO 2007; 25:2019-26.

             Thürlimann B. Reducing the risk of early recurrence in hormone-
             responsive breast cancer. Ann Oncol 2007; 18 Suppl 8:viii8-17.

             ruhstaller t, Thürlimann B, koeberle d, von Moos R. Is surgery still part of
             local therapy in patients with locally advanced esophageal carcinoma?.
             JCO 2007; 25:4025-6; author reply 4026-7.

             Seeholzer N, Thürlimann B, koeberle d, Hess D, Korte W. Combining
             chemotherapy and low-molecular-weight heparin for the treatment of
             advanced breast cancer: results on clinical response, transforming
             growth factor-beta 1 and fibrin monomer in a phase II study. Blood
             coagulation & fibrinolysis : an international journal in haemostasis and
             thrombosis 2007; 18:415-23.

                                                                            32
Publikationen
             Titel

Wissensch-   Salzberg M, Thürlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann
aftlicher    A, ruhstaller t, Stopatschinskaja S, von Moos R. Pegylated liposomal
Artikel/     doxorubicin (caelyx) in metastatic breast cancer: a community-based
Review       observation study. Oncology 2007; 72:147-51.

             Ribi K, Bernhard J, Rufibach K, Thürlimann B, von Moos R, ruhstaller t,
             Glaus A, Böhme C. Endocrine symptom assessment in women with breast
             cancer: what a simple "yes" means. JSCC 2007; 15:1349-56.

             Hess D, koeberle d, Thürlimann B, Pagani O, Schonenberger A, Mattmann
             S, Rochlitz C, Rauch D, Schuller J C, Ballabeni P, Ribi K, Swiss Group for
             Clinical Cancer Research . Capecitabine and vinorelbine as first-line
             treatment in elderly patients (> or =65 years) with metastatic breast
             cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73:228-37.

             Coates A S, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J
             F, Paridaens R, Castiglione-Gertsch M, Gelber R D, Colleoni M, Láng I, Del
             Mastro L, Smith I, Chirgwin J, Nogaret J M, Pienkowski T, Wardley A,
             Jakobsen E H, Price K N, Goldhirsch A. Five years of letrozole compared
             with tamoxifen as initial adjuvant therapy for postmenopausal women
             with endocrine-responsive early breast cancer: update of study BIG 1-98.
             JCO 2007; 25:486-92.

             Thürlimann B, koeberle d, Senn H J. Guidelines for the adjuvant
             treatment of postmenopausal women with endocrine-responsive breast
             cancer: past, present and future recommendations. EJC 2007; 43:46-52.

                                                                           33
Publikationen
             Titel

Wissensch-   International Breast Cancer Study Group , Colleoni M, Gelber S,
aftlicher    Simoncini E, Pagani O, Gelber R D, Price K N, Castiglione-Gertsch M,
Artikel/     Coates A S, Goldhirsch A. Effects of a treatment gap during adjuvant
Review       chemotherapy in node-positive breast cancer: results of International
             Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Ann Oncol
             2007; 18:1177-84.

             Kapp U, Fürstenberger G. Die Primärbehandlung des frühen
             Mammakarzinoms : Internationale St. Gallen-Konsensus Konferenz 2007.
             Schweizer Zeitschrift für Onkologie 2007; 4:6-10.

             . Brustzentren in der Schweiz. Schweizer Zeitschrift für Onkologie 2007;
             4:22-23.

             Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann
             B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret J M, Gelber R D,
             Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio
             M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group ,
             International Breast Cancer Study Group . Predictors of early relapse in
             postmenopausal women with hormone receptor-positive breast cancer in
             the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.

             koeberle d, Thürlimann B. Letrozole as upfront endocrine therapy for
             postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
             Breast Cancer Res Treat 2007; 105 Suppl 1:55-66.

             Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins
             J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price K N, Pagani O,
             Simoncini E, Castiglione Gertsch M, Gelber R D, Coates A S, Goldhirsch A.
             CA15-3 and alkaline phosphatase as predictors for breast cancer
             recurrence: a combined analysis of seven International Breast Cancer
             Study Group trials. Ann Oncol 2007; 18:701-8.

                                                                          34
Publikationen
             Titel

Wissensch-   Klaeser B, Wiederkehr O, koeberle d, Mueller A, Bubeck B, Thürlimann B.
aftlicher    Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron
Artikel/     emission tomography in the pre- and postoperative staging of patients
Review       with clinically intermediate or high-risk breast cancer. Ann Oncol 2007;
             18:1329-34.

             Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber R D,
             Forbes J F, Murray E, Collins J, Aebi S, Thürlimann B, Price K N,
             Goldhirsch A, Coates A S, International Breast Cancer Study Group Trial
             VIII . Adjuvant chemotherapy followed by goserelin compared with either
             modality alone: the impact on amenorrhea, hot flashes, and quality of life
             in premenopausal patients--the International Breast Cancer Study Group
             Trial VIII. JCO 2007; 25:263-70.

             Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M,
             Dietrich D, Clément P, koeberle d, Goldhirsch A, Thürlimann B. Clinical
             benefit of fulvestrant in postmenopausal women with advanced breast
             cancer and primary or acquired resistance to aromatase inhibitors: final
             results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK
             21/00). Ann Oncol 2007; 18:64-9.

             Goldhirsch A, Coates A S, Gelber R D, Glick J H, Thürlimann B, Senn H J,
             St Gallen Expert Panel Members . First--select the target: better choice of
             adjuvant treatments for breast cancer patients. Ann Oncol 2006;
             17:1772-6.

             Glaus A, boehme c, Thürlimann B, ruhstaller t, Hsu Schmitz S F, Morant
             R, Senn H J, von Moos R. Fatigue and menopausal symptoms in women
             with breast cancer undergoing hormonal cancer treatment. Ann Oncol
             2006; 17:801-6.

                                                                           35
Publikationen
             Titel

Wissensch-   Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn H J,
aftlicher    Hamacher J, Boneberg E M. Circulating endothelial cells and angiogenic
Artikel/     serum factors during neoadjuvant chemotherapy of primary breast
Review       cancer. BJC 2006; 94:524-31.

             ruhstaller t, Roe H, Thürlimann B, Nicoll J J. The multidisciplinary
             meeting: An indispensable aid to communication between different
             specialities. EJC 2006; 42:2459-62.

             Langenegger T, Wahl P, Schiesser D, Thürlimann B. Plasma levels of
             tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with
             metastatic breast cancer and chronic hemodialysis. Breast Cancer Res
             Treat 2006; 100:177-81.

             Maschke U, Kränzlin M, Krapf R, Pecherstorfer M, Strebel U, Thürlimann
             B. Übersicht Bisphosphonate. Pharmakritik 2006; 28:17-20.

             Thürlimann B. Aromatasehemmer in der modernen Brustkrebstheraphie.
             Bulletin Leben wie zuvor 2006; 66:19-22.

             koeberle d, Thürlimann B. Letrozole as adjuvant endocrine therapy in
             postmenopausal women with breast cancer. Expert review of anticancer
             therapy 2006; 6:5-10.

             koeberle d, Thürlimann B. Adjuvant endocrine therapy in postmenopausal
             breast cancer patients. Breast (Edinburgh, Scotland) 2005; 14:446-51.

             Breast International Group (BIG) 1-98 Collaborative Group , Thürlimann
             B, Keshaviah A, Coates A S, Mouridsen H, Mauriac L, Forbes J F,
             Paridaens R, Castiglione-Gertsch M, Gelber R D, Rabaglio M, Smith I,
             Wardley A, Wardly A, Price K N, Goldhirsch A. A comparison of letrozole
             and tamoxifen in postmenopausal women with early breast cancer. NEJM
             2005; 353:2747-57.

                                                                           36
You can also read